|Date||Title|| || |
|03/06/18||Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update|
|EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing
Expecting at least five clinical-stage programs by end of 2022 as part of EM22 five-year goals
Year-end cash, cash equivalents, and marketable securities of $329 million expected to fund business for at least 24 months
CAMBRIDGE, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results ... || |
|02/28/18||Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases|
|CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the Company has joined forces with 30 million Americans and health care advocates around the world for Rare Disease Day® today. Rare Disease Day is an annual awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people face.
“The team at Editas Medicine has the bold vision to unlock the p... || |
|02/27/18||Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results|
|CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 6th, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2017.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 2449529. A live webcast of the presentation will be available ... || |
|02/16/18||Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors|
|CAMBRIDGE, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield will also serve on the Audit Committee of the Board.
Dr. Hopfield is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She is currently the Chairperson of the Board of Trustees of the Josl... || |
|02/08/18||Editas Medicine to Participate in Upcoming Investor Conferences|
|CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor conferences. Details are as follows:
BIO CEO & Investor Conference
Monday, February 12, 2018
1:30 p.m. ET
... || |
|01/08/18||Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference|
|By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials
Announces first acquisition with purchase of certain assets from i2 Pharmaceuticals and its affiliates, further strengthening Editas’ guide RNA chemistry capabilities and intellectual property
Provides updates on advancements in ocular and engineered cell medicine programs
CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NE... || |
|01/03/18||Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference|
|CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018, at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco, CA.
A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas... || |